Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SGP
SGP logo

SGP Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy SpyGlass Pharma Inc (SGP) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
19.520
1 Day change
2.25%
52 Week Range
32.440
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

SGP is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is near flat on the day, has no strong proprietary buy signal, no recent news catalyst, and no meaningful institutional or insider buying support. While the technical setup is not bearish, it is also not strong enough to justify an immediate purchase for an impatient investor. I would wait for a clearer breakout or better confirmation before buying.

Technical Analysis

The technical picture is mixed to neutral. Price closed at 19.11, slightly below the previous close of 19.15. RSI_6 at 42.32 sits in the neutral-to-weak zone, showing limited momentum. MACD histogram is positive at 0.29 but is contracting, which suggests upside momentum is fading. Moving averages are converging, pointing to a consolidation phase rather than a strong trend. Key levels to watch are support at 18.655 and resistance at 20.366. Overall, the stock is range-bound with no clear bullish trend.

Positive Catalysts

  • No news in the recent week, which means no fresh negative event pressure and no event-driven catalyst currently. The stock trend model suggests a 2.87% move higher over the next month based on similar candlestick patterns, which is mildly supportive. Technical support near 18.655 could attract buyers if held.

Neutral/Negative Catalysts

  • No recent news means no immediate catalyst to drive a re-rating. Hedge funds are neutral with no significant trading trends over the last quarter, and insiders are also neutral over the last month, so there is no visible smart-money accumulation. AI Stock Picker shows no signal, and SwingMax shows no recent signal, removing two potentially bullish trading triggers. The price is also below the pivot level of 20.366, which keeps the stock in a weaker near-term posture.

Financial Performance

Financial snapshot data was unavailable due to an error, so the latest quarter financials and growth trends cannot be assessed. As a result, there is no confirmed evidence here of accelerating revenue, earnings, or margin improvement for the latest quarter season.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no visible Wall Street upgrade/downgrade trend to support a buy case. Based on the available information, the pro view is weak: no positive analyst momentum, no insider accumulation, no hedge fund support, and no recent news catalyst. The con view is stronger because the stock lacks confirmation from both fundamentals and sentiment.

Wall Street analysts forecast SGP stock price to rise
0 Analyst Rating
0
Wall Street analysts forecast SGP stock price to rise
0 Buy
0 Hold
0 Sell
0
Current: 19.090
sliders
Low
0
Averages
0
High
0
0
Current: 19.090
sliders
Low
0
Averages
0
High
0
H.C. Wainwright
Yi Chen
initiated
$37
AI Analysis
2026-03-10
Reason
H.C. Wainwright
Yi Chen
Price Target
$37
AI Analysis
2026-03-10
initiated
Reason
H.C. Wainwright analyst Yi Chen initiated coverage of SpyGlass Pharma with a Buy rating and $37 price target. SpyGlass is a clinical-stage biopharmaceutical company focused on the development of long-acting, sustained drug delivery of approved medicines, the analyst tells investors in a research note. The firm believes the company's bimatoprost solve the issue of patient non-compliance for prescribed topical medications, which could lead to better control of intraocular pressure.
Stifel
initiated
$42
2026-03-03
Reason
Stifel
Price Target
$42
2026-03-03
initiated
Reason
Stifel initiated coverage of SpyGlass Pharma with a Buy rating and $42 price target. The firm says that by combining a known drug, a known procedure, and a known device, SpyGlass' sustained-release drug-delivery BIM-IOL is "poised to capitalize on the ongoing interventional glaucoma secular shift." The BIM-IOL U.S. total addressable market is large at $13B annually, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for SGP
Unlock Now

People Also Watch